Med-tech companies secured $2.76 billion across financings 56 transactions in January 2025, up from $1.72 billion in December and $919.99 million in November.

The immediate implementation of the U.S. NIH’s guidance to cut indirect costs included in its grants to 15% was quickly halted late Feb. 10 when a federal district judge granted a nationwide temporary ...

Researchers from the QIMR Berghofer Medical Research Institute in Queensland, Australia and Emory University have shown that a potential new targeted therapy for childhood brain cancer was effective ...

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

This current administration is like nothing that we've seen before,” said a managing partner of a global venture capital firm who spoke to BioWorld on the condition of anonymity. “President Trump’s ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its ...

The med tech patent wars conscripted another two companies via a patent infringement lawsuit between Inari Medical Inc. and Imperative Care Inc. — a struggle that is playing out in a California ...

The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging ...

CSPC Pharmaceutical Group Ltd. has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for SYS-6017, an mRNA vaccine to prevent herpes zoster infections.

At the recent annual congress of the European Association for Haemophilia and Allied Disorders, researchers from Novalgen Ltd. presented the discovery and preclinical characterization NVG-444, a ...

Researchers from Fudan University and Southwest University published data from a study that detailed the development of a novel vertebrate model suitable for high-throughput screening of potential ...

Raising money to advance promising science is a constant struggle, bringing biopharma executive leadership together to learn about investment strategies in the opening session at the Biotechnology ...